Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
about
Immunotoxicity of monoclonal antibodiesDiagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor TherapyWhat is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?Golimumab for the treatment of ulcerative colitisTuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.Can ELISpot replace the tuberculin skin test for latent tuberculosis?Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Crohn's disease: the first visitCurrent and emerging drugs for the treatment of inflammatory bowel disease.Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.Risk of tuberculosis reactivation with tofacitinib (CP-690550).Update on the natural history and systemic treatment of psoriasis.Infectious complications associated with monoclonal antibodies and related small moleculesTherapeutic options in acute severe ulcerative colitis.Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations.Managing immunosuppression in medical patients.A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.Crohn's disease: the subsequent visit.Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease.Biological therapies for inflammatory bowel disease: controversies and future options.Opportunistic infections due to inflammatory bowel disease therapy.Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops.Health maintenance and inflammatory bowel disease.Infection risk associated with anti-TNF-α agents: a review.Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.Perianal Crohn's disease: is there something new?Reactivation of latent tuberculosis in a Crohn's patient after TB prophylaxis treated with adalimumab.European consensus on the histopathology of inflammatory bowel disease.Primary nasal tuberculosis during anti-tumour necrosis factor alpha treatment of a patient with rheumatoid arthritis.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.Prospective evaluation of the clinical utility of interferon-γ assay in the differential diagnosis of intestinal tuberculosis and Crohn's disease.Polymorphisms in tumor necrosis factor and lymphotoxin A in tuberculosis without and with response to treatment.
P2860
Q24653374-AD61F6A9-72FD-4AFC-AB33-A5AAC4B183E7Q27005716-8C0AF44D-DD82-42DF-B1FB-0EFBB720B05AQ27687191-3246775C-E53E-418E-87B4-D36EB5019044Q28236322-2E858C76-DB6D-401F-A71A-29C3F779A6F0Q30799235-487AFE6C-2766-4A5F-92AD-FE0D6458010CQ33524774-7DEAB190-ECE4-4C86-9015-71A2EE036D84Q33882852-941D7DB9-1D55-48A4-B083-9DE837852687Q34027648-AB6C9A8C-4277-4838-B70C-7B234A08E4C9Q34811529-0FCC1A9B-1C8F-4A2A-9534-FF940BAB3F0DQ34883210-D21BCBF0-A543-489E-AB5C-19C760CFA8ABQ35188622-85226E71-3CFE-4AAC-ADFC-27658EB70185Q36153907-37AFC5D6-0EC3-4C6E-8C85-3CADCCF7BE81Q37081486-B48F383B-1ADA-4D32-A460-013146FB08C5Q37156636-2F2E4B72-F680-4DA0-9499-E1FBD61A5087Q37345935-1878D1F0-D2DA-462E-8CF7-C126C80D9D03Q37492482-1106E333-02F8-45C6-9307-419A3383C9BAQ37544228-09895E7E-B1D7-4B26-8191-BD5E3F5B1F64Q37678199-84C2DD91-DB61-4BB2-92B3-1708917EA1D1Q37685135-A351083F-840C-47C4-84ED-682D091FACEEQ37789689-D2440A19-D3CB-41CF-880C-04C4900E6122Q37960183-AC9ACE58-6D27-4CD7-920D-88DADFF19BFEQ38139812-5FC0E20B-0356-4E8F-9960-2C41D1B96E4BQ38197891-C36FA9CC-9F45-4288-9BD1-7285E67998B4Q38247077-0E4C7408-4C8E-470A-B4F1-D1D842B619D0Q38335718-8F65572E-9A7D-4B0D-BA0A-65166F383E0FQ39116859-621C263B-FE31-4A5A-BFC8-15505A170C15Q39147818-1E5BD3ED-72A9-4119-AD16-1800FBBE3AFCQ42722418-91BC5943-C17B-4A9A-A0BA-2F7DB3BEA275Q44229919-64040442-6754-429A-80F0-47D62229E68FQ46690820-2C58D063-4981-4337-9397-E3AAA35260CEQ47749372-733DFA1E-B83D-4B14-8FA4-865732C58DD7Q49508046-C94F7B3B-1548-4725-8FDB-547CD3E501B8Q50098937-49BA4595-EC85-4E63-A148-B91DB6D8334DQ53452028-A8635A10-8529-45D8-8C0D-ED053C2BABBEQ54440115-7E74CA07-3A59-4B30-8214-33FCB78D3B0A
P2860
Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Review article: minimizing tub ...... of inflammatory bowel disease.
@en
type
label
Review article: minimizing tub ...... of inflammatory bowel disease.
@en
prefLabel
Review article: minimizing tub ...... of inflammatory bowel disease.
@en
P2860
P921
P1476
Review article: minimizing tub ...... of inflammatory bowel disease.
@en
P2093
P2860
P356
10.1111/J.1365-2036.2007.03553.X
P407
P577
2007-10-16T00:00:00Z